Joint effect of G1691A factor V point mutation and factor VII Arg/Gln353 gene polymorphism on the risk of premature coronary artery disease

Annales de Genetique

Volumn 44, Issue 1, 2001, Pages 33-36

  Petrovič, Daniel ^a,b   Zorc, M ^b   Keber, I ^a   Peterlin, B ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Factor VII Arg; G1691A factor V point mutation; Gln353 gene polymorphism; Premature coronary artery disease; Risk factors; Synergy

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; GLUTAMINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; POINT MUTATION; RISK FACTOR; SLOVENIA;

EID: 0035026786     PISSN: 00033995     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3995(00)01031-5     Document Type: Article

References (20)

1. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V is associated with resistance to activated protein C. Nature. 1:1994;64-67.
2. Bockxmeer F.M., Baker R.I., Taylor R.R. Premature ischaemic heart disease and the gene for coagulation factor V. Letters to the editor. Nature Medicine. 359:1995;185-185.
3. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 106:1992;641-644.
4. Castelli W.P. Cardiovascular disease and multifactorial risk: challenge of thes. Am. Heart J. 97:1983;1191-1200.
5. Doggen C.J.M., Cats V.M., Bertina R.M., Rosendaal F.R. Interaction of coagulation defects and cardiovascular risk factors. Circulation. 11:1998;1037-1041.
6. Green F., Kellher C., Wilkes H., Temple A., Meade T., Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioslc. Thromb. 1991;540-546.
7. Green F., Humphries S. Genetic determinants of arterial thrombosis. Baillieres Clin. Haematol. 76:1994;7675-7692.
8. Handin R.I. Disorders of coagulation and thrombosis. Isselbacher K.J, Braunwald E, Wilson J.D, Martin J.B, Fauci A.S, Kasper D.L. Harrison's principles of internal medicine. 14th edition :1994;1804-1810 McGraw-Hill, New York, St. Louis, London.
9. Heywood D.M., Ossei-Gerning N., Grant P.J. Association of factor VII:C levels with environmental and genetic factors in patients with ischemic heart disease and coronary atheroma characterised by angiography. Thromb. Haemost. 239:1996;161-165.
10. Holm J., Zoeller B., Berntorp E., et al. Prevalence of factror V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J. Intern. M. 338:1996;221-226.
11. Iacoviello L., Di Castelnuovo A., De Knijff P., et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. M. 119:1998;79-85.
12. 353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis. 94:1996;119-127.
13. Lane A., Cruickshank J.K., Mitchell J., Henderson A., Humphries S., Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnick groups at different risk of coronary heart disease. Atherosclerosis. 2:1992;43-50.
14. Maede T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischemic heart disease. Principal results of the Northwick Park Heart Study. Lancet. 78:1987;533-537.
15. Miller G.J., Cruickshank J.K., Thompson R.L., et al. Fat consumption and factor VII coagulant activity in middle-aged men. Atherosclerosis. 332:1989;19-24.
16. Ridker P.M., Hennekens C.H., Lindpainter K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and deep venous thrombosis in apparently healthy men. N. Engl. J. M. 89:1995;912-917.
17. Rosendaal F.R., Siscovick D.S., Schwartz S.M., et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 344:1997;1747-1750.
18. Samani N.J., Lodwick D., Martin D.S., Kimber P. Letters to the editor. Resistance to activated protein C and risk of premature myocardial infarction. Lancet. 17:1994;1709-1710.
19. Wang X.L., Wang J., McCredie R.M., Wilckeb D.E.L. Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 727:1997;246-251.
20. WHO Tech. Rep. Ser. 1985;9-10.